(PRWEB) March 08, 2013
This study, http://onlinelibrary.wiley.com/doi/10.1111/bph.12139/abstract soon to be published in the British Journal of Pharmacology and available now as an abstract online, delineates the mechanisms by which minocycline reduces inflammation. This peer-reviewed article critically reviews recent human and animal research demonstrating the potential for minocycline to provide neuroprotection and ameliorate the impairments experienced by those affected by traumatic brain injury (TBI), stroke and Alzheimer's disease. The authors elucidate how minocycline exerts neuroprotective and neuroregenerative effects in response to TBI, stroke and Alzheimer's. These processes are entirely different from those of etanercept. Perispinally administered etanercept inhibits the production of TNF-alpha in the brain. Minocycline also inhibits the production of TNF-alpha as well as a number of related cytokines. In 2012 Augusto Ramirez, M.D., began treating TBI, stroke and Alzheimer’s patients with perispinal Enbrel coupled with oral minocycline. The result has been improved outcomes. This article: Minocycline: Far beyond an Antibiotic provides broad scientific rationale for the inclusion of oral minocycline adjunctively with perispinally administered etanercept for the treatment of TBI, stroke and Alzheimer's disease.
Neurological Wellness Center began holding perispinal injection technique training courses in the spring of 2011. Since then physicians, nurses and lay caregivers have come from around the world to their Center in Managua, Nicaragua for individualized instructional courses teaching this procedure. Presently Neurological Wellness Center remains the only institution in the world teaching this perispinal Enbrel injection procedure. For more information about Neurological Wellness Center’s perispinal injection courses visit: http://reversealzheimersnow.com.
For many, flying to Managua, Nicaragua to receive this personalized training is an enormous expense and inconvenience. To overcome this problem, Neurological Wellness Center, under the direction of Augusto Ramirez, M.D., created Perispinal Enbrel Step-By-Step Instructional Video and accompanying e-book. This 24-minute video and 37-page e-book are now available online at http://www.neurological-recovery-guide.com.
Augusto Ramirez, M.D., Director of Neurological Wellness Center, a private medical group in Managua Nicaragua, authorized this press release.
Neuroinflammation contributes to a portion of the impairments people with Traumatic Brain Injury, stroke and Alzheimer’s disease experience. Last year a study published in the Journal CNS Drugs and available online: http://www.ncbi.nlm.nih.gov/pubmed/23100196, systematically examined the clinical responses of 629 patients afflicted by stroke or traumatic brain injury following the perispinal administration of Enbrel (Etanercept). The mean age of the stroke patients was 65.8 years. The mean interval between stroke and perispinal Enbrel treatment (PSE) was 42.0 months. The mean age of the traumatic brain injury (TBI) patients was 34.7 years. The mean interval between TBI and PSE treatment was 115 months.
Comprehensive pre-treatment and post-treatment assessments were made, with particular attention given to motor function, walking, pain, sensation, cognition and mood. A variety of standardized instruments were utilized in making these assessments. Neurological Wellness Center finds the results of this study to be extraordinarily noteworthy, not simply for the degree of the improvements observed but also for the extent of improvements across many areas of assessment. Equally striking was the rapidity of the improvement. Observations such as “rapid motor improvement beginning within minutes: was routinely observed in both post-stroke and the TBI patients” are ubiquitous throughout this observational study. The fact that the mean interval between stroke and PSE was 42.0 months and TBI and PSE 115 months makes these results even more remarkable. These results herald a new paradigm of understanding stroke and traumatic brain injury; whereby a self-perpetuating cascade of inflammation is produced in response to the trauma and the on-going inflammation contributes substantially to the impairments people experience. Once this inflammation is attenuated, significant recovery of physical and cognitive function becomes a reality these people experience often for the first time in years.
"The addition of minocycline to our treatment protocol has resulted in improved treatment outcomes." Augusto Ramirez M.D.
Dr. Steve Ralph, Associate Professor at Griffith University School of Medicine in Australia came to our Neurological Wellness Center in Managua and received instruction in perispinal Enbrel injection procedure. Dr. Ralph has stated; "These results represent a sea change in therapeutic possibilities for stroke and TBI patients. I have observed first hand rapid clinical improvement in patients. Rarely do we see such a radical breakthrough in medical treatment as this."
The TBI treatment, stroke treatment and Alzheimer’s treatment protocols Dr. Augusto Ramirez utilizes all involve combining perispinal Enbrel injections with oral minocycline. Additionally, he advises supplementing with N-acetylcysteine, fish oil and astaxanthin. To learn more about ameliorating the impairments caused by TBI, stroke and Alzheimer’s disease by reducing inflammation in the brain visit: http://www.neurological-recovery-guide.com. To schedule a personal hands-on training covering all aspects of perispinal Enbrel injection procedure visit: http://www.reversealzheimersnow.com. For the lowest Enbrel price in North American visit: http://www.genuine-enbrel-cheaper.com/
Clinical Trial; Minocycline in patients with Alzheimer's disease.
Clinical Trial; Minocycline treatment in acute stroke; An open label, evaluator-blinded study.
Clinical Trial; Safety of minocycline in the treatment of traumatic brain injury (TBI)
Minocycline to improve neurologic outcome in stroke; a dose-finding study.
Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models.
Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease.
Analysis of the antibiotic minocycline as a treatment for dementia.
Minocycline reduces traumatic brain injury-mediated capase-1 activation , tissue damage and neurological dysfunction.
Therapeutic evaluation of etanercept in a model of traumatic brain injury.
Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases.
Tumour necrosis factor-alpha is increased in the cerebrospinal fluid and serum of ischaemic stroke patients and correlates. with the volume of evolving brain infarct.
Perispinal etanercept for neuroinflammatory disorders.
Inflammatory cytokines in acute ischemic stroke.
Efficacy of minocycline in acute ischemic stroke: A single-blinded, placebo-controlled trial.
Minocycline Reduces Stroke Damage in Late-Presenting Patients.
Minocycline treatment in acute stroke.
Inflammatory markers and stroke.
Cognitive and neurological improvement after the INR’s patented etanercept treatment four years after stroke.
Rapid improvement 8 years after stroke with the patented INR treatment.
Effects of Etanercept and Minocycline in a rat model of spinal cord injury.
TNF-alpha modulation for treatment of Alzheimer's disease, 6-month pilot study.
MedGenMed 2006, 8:25. PubMed Abstract, Demonstrates the efficacy of perispinal Enbrel as a treatment for Alzheimer's disease.
Novel drug therapy immediately reverses Alzheimer's cognitive deficits.
Reversal of Alzheimer's symptoms within minutes in human study.
Perispinal etanercept: a new therapeutic paradigm in neurology.
Enbrel injections reverse some Alzheimer’s disease symptoms.
Tobinick, E.L. and H. Gross, Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC Neurol, 2008. 8: p.27.
Tobinick, E.L. and H. Gross, Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflammation, 2008. 5: p.2.
Griffin, W.S., Perispinal etanercept: potential as an Alzheimer’s therapeutic. J Neuroinflammation, 2008. 5: p.3.
Tobinick, E., Perispinal etanercept for treatment of Alzheimer’s disease. Curr Alzheimer Res, 2007. 4(5): p.550-2.
McAlpine, F.E. and M.G. Tansey, Neuro-inflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s. J Inflammation Research, 2008. 1: p.29 39.
Read the full story at http://www.prweb.com/releases/2013/3/prweb10424735.htm.
Copyright©2012 Vocus, Inc.
All rights reserved